Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-5

Solid result. 20 million would have been outstanding IMO. Expect higher expenses but cash build is still good. EPP revenues can only get better over time and if they keep the price 'consistently' high it's a good earner on it's own. We need the new catalyst to go to next level and I feel OTC will be the one but revenues will take time. There's numerous other potential catalysts like paediatric TTT, Stroke, Pigmentosa/DNA repair, other potential label additions and the elusive 6th indication. Of course you only know what you know so who knows outside the company but it's still exciting IMO. I feel 2-5 years still to go for triple digits. GLTA